Compare FDS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDS | CYTK |
|---|---|---|
| Founded | 1978 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 8.0B |
| IPO Year | 1996 | 2004 |
| Metric | FDS | CYTK |
|---|---|---|
| Price | $207.67 | $62.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 17 |
| Target Price | ★ $311.10 | $85.24 |
| AVG Volume (30 Days) | 876.1K | ★ 1.7M |
| Earning Date | 03-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 12.60 | N/A |
| EPS | ★ 15.72 | N/A |
| Revenue | ★ $2,360,702,000.00 | $87,211,000.00 |
| Revenue This Year | $6.56 | $341.94 |
| Revenue Next Year | $5.30 | $50.15 |
| P/E Ratio | $13.19 | ★ N/A |
| Revenue Growth | 5.88 | ★ 2609.26 |
| 52 Week Low | $201.80 | $29.31 |
| 52 Week High | $474.79 | $70.98 |
| Indicator | FDS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 22.43 | 44.41 |
| Support Level | $201.80 | $60.05 |
| Resistance Level | $234.33 | $67.10 |
| Average True Range (ATR) | 12.64 | 2.56 |
| MACD | -7.50 | -0.34 |
| Stochastic Oscillator | 13.07 | 19.23 |
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.